CELG News and Press, Celgene Corporation From 06/18/19

With very beneficial results obtained for the treatment of psoriasis, Dermavant Sciences ( DRMT ) is a name to be followed closely after the IPO goes live. Besides, the Phase 3 clinical results are expected in the first half of 2020. So, market participants willing to profit on this name shoul...

Nothing strengthens authority so much as silence. " - Leonardo da Vinci Today, we look at a small, early-stage development firm trying to use the body's immune system to attack tumors. Company Overview: Jounce Therapeutics ( JNCE ) IPO'd in 2017 and is a Massachusetts-based clinical...

BeiGene ( BGNE ) will get back its rights to tislelizumab from Celgene ( CELG +0.4% ) plus $150M ahead of Celgene's merger with Bristol-Myers Squibb. More news on: BeiGene, Ltd., Celgene Corporation, Healthcare stocks news, Read more ...

NEW YORK , June 14, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced that Kinza Kasher of Leoplus USA was chosen as the w...

Celgene ( CELG ) is in good shape in terms of its multiple sclerosis ((MS)) drug ozanimod. That's because it announced that regulatory applications for the drug was accepted by both the FDA and EMA. This gives the company the potential to obtain approval for both territories. Getting thi...

The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts ...

The FDA and EMA have accepted for review Celgene's (NASDAQ: CELG ) marketing applications seeking approval to use ozanimod to treat relapsing forms of multiple sclerosis. More news on: Celgene Corporation, Bristol-Myers Squibb Company, Healthcare stocks news, Read more ...

Experienced leadership team and evolved structure position company to drive in-line business, launch new products and create long-term value through broad pipeline Company well positioned for long-term growth, with strategic focus on Oncology, Hematology, Immunology, Cardiovascul...

Data show the potential of investigational anti-CD19 chimeric antigen receptor T-cell therapy in patients with previously treated blood cancers, including those with high-risk disease Celgene Corporation (NASDAQ: CELG) today announced that data from the TRANSCEND CLL 004 and TRANSCEND...

We’re enjoying our research on BioSig ( BSGM ) and its electrophysiology device, the PURE EP, which we believe has little to no usefulness. The information that we keep coming across continues to be juicy and new developments are occurring. If you missed our previous BioSig report pu...